4-Hydroxytamoxifen (Afimoxifene)

Name: 4-Hydroxytamoxifen (Afimoxifene)
Brand: Selleck Chemicals
SKU: S7827
Rating: 5 (9 reviews)

For research use only.

Catalog No.S7827 Synonyms: Afimoxifene

9 publications

4-Hydroxytamoxifen (Afimoxifene) Chemical Structure

CAS No. 68392-35-8

4-Hydroxytamoxifen (Afimoxifene) is the active metabolite of tamoxifen and a selective estrogen receptor (ER) modulator that is widely used in the therapeutic and chemopreventive treatment of breast cancer. It activates on-target modification frequency for intein-Cas9 variants.

Selleck's 4-Hydroxytamoxifen (Afimoxifene) has been cited by 9 publications

Nat Methods, 2017, 14(9):891-896

PubMed: 28737741 ( click the link to review the publication )

BMC Dev Biol, 2021, 21(1):4

PubMed: 33517884 ( click the link to review the publication )

Breast Cancer Res, 2021, 23(1):26

PubMed: 33602273 ( click the link to review the publication )

Adv Sci (Weinh), 2020, 7(20):2000157

PubMed: 33101843 ( click the link to review the publication )

Cell Rep, 2020, 30(1):25-36

PubMed: 31914391 ( click the link to review the publication )

Br J Cancer, 2020, 10.1038/s41416-020-01174-z

PubMed: 33257837 ( click the link to review the publication )

Cells, 2019, 8(6)

PubMed: 31216647 ( click the link to review the publication )

J Cell Physiol, 2019, 10.1002/jcp.28910

PubMed: 31141164 ( click the link to review the publication )

Oncogene, 2017, 36(16):2255-2264

PubMed: 27748766 ( click the link to review the publication )

1 Customer Review

CDK4/6 inhibitor resistance promotes diminished ER expression and activity. (a and b) Proliferation of MCF-7 and MR cells in the presence of different concentrations of ICI (a) or 4-hydroxytamoxifen (4-OHT) (b) was measured by the alamarBlue assay and plotted as % inhibition of proliferation against log concentration of inhibitor. Each data point represents the average value±s.d. of six replicates obtained in three independent experiments.

Oncogene, 2016, 36(16):2255-2264. 4-Hydroxytamoxifen (Afimoxifene) purchased from Selleck.

Purity & Quality Control

Choose Selective Estrogen/progestogen Receptor Inhibitors

Biological Activity

Description

In vitro

4-OHT is a potent activator of ER and has been shown to have a higher affinity for estrogen receptors compared to tamoxifen. It has significant dose and time-dependent direct effects to alter the contractile function of isolated adult rat cardiac myocytes^[1]. 4-HT activates on-target modification frequency for intein-Cas9 variants ^[3].

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Activity Description	PMID
MCF7 cells	NX;0Z21pWHKxbHnm[ZJifGmxbjDhd5NigQ>?			Ml\3TY5pcWKrdHnvckBw\iCnc4Tyc4dmdi2\|dHnteYxifGWmIF3DSk04KGOnbHygdJJwdGmoZYLheIlwdixiSVO1NF0xNjVibl2=	M2PBZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493Nzl3NEi4NVcoRjl3NEi4NVc9N2F-
MCF7	NI\nO4NHfW6ldHnvckBie3OjeR?=			NXL2W5JSTW[oZXP0bZZmKGSxc3Wg[o9zKFt\|SG2tJIV{fHKjZHnvcEBi\2GrboP0JJBzd2yrZnXyZZRqd25ib3[gUWNHNTdiY3XscJMtKEWFNUCgQUAxNjByMECzJO69VS5?	NUHiWpR7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke2PVY5OSd-Mke2PVY5OTxxYU6=
MCF7	NVvjTZRVTnWwY4Tpc44h[XO\|YYm=		MVm0JIhzew>?	Mn7GTY5lfWO2aX;uJI9nKEWUYXzwbIEh\GWpcnHkZZRqd25iaX6gbJVu[W5iTVPGO{Bk\WyuczDpckBxcGWwb3ygdoVlKG[{ZXWgVnBOUSCvZXTpeY0h[2:wdHHpcolv\yB3JTDjbIFz[2:jbDDk[Zh1emGwLYTy[YF1\WRiRlLTJIlv[3WkYYTl[EBnd3JiNDDodpMh[nliU2CxJIFv\CCjboTpMWVTKHKjYnLpeEBud26xY3;scoFtKGGwdHnic4R6KGKjc3XkJIlvNWOnbHygW4V{fGW{bjDhd5NigSxiQXP0bZZqfHliPTCwMlAxODFizszNMi=>	M1u0TVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyMEi2OlI3Lz5\|MEC4OlYzPjxxYU6=
MCF7	MWTGeY5kfGmxbjDhd5NigQ>?			MkfsSYZn\WO2aY\lJINwdmOnboTyZZRqd25iYXfhbY5{fCCPQ1[tO{BjemWjc4SgeJVud3JiY3XscJMhfXOrbnegUWNHNTdiYYPzZZktKEWFNUCgQUAxNjByMEGyJO69VS5?	MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yOjh{NUmzOUc,OTJ6MkW5N\|U9N2F-
MCF7	NVPGeZZFSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=			NWHkfpZxSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDNR2Y4KGOnbHzzMEBKSzVyIE2gNE4xODB3IN88UU4>	M1n1ZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{NEC1Nlg3Lz5{MkSwOVI5PjxxYU6=
MCF7	MV3BcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?			M2XOemFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTVPGO{Bk\WyuczygTWM2OCB;IECuNFAxPTN5IN88UU4>	M4fvTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4NEC3NFEzLz5{NkSwO\|AyOjxxYU6=
MCF	M2HHXWZ2dmO2aX;uJIF{e2G7			M3PkOGFvfGGpb37pd5Qh[WO2aY\peJkh[XRicILv[4V{fGW{b37lJJJm[2WydH;yJIlvKGi3bXHuJG1ETiClZXzsd{Bie3Onc4Pl[EBieyCnc4TyZYRqd2xvaX7keYNm\CC{ZXPldJRweiC{ZYPwc45{\SxiSVO1NEA:KDBwMECwO\|k1OyEQvF2u	MkjNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ2MEewNVIoRjJ4NEC3NFEzRC:jPh?=
Ishikawa endometrial cells	Mo\YSpVv[3Srb36gZZN{[Xl?			M{D1d2Fod26rc4SgZYN1cX[rdImgZZMh[WytYXzpcoUheGixc4DoZZRie2ViaX7keYN1cW:wIHnuJGl{cGmtYYfhJIVv\G:vZYTybYFtKGOnbHzzJINwdXCjcnXkJJRwKEV{LDDFR\|UxKD1iMD6wNFA5KM7:TT6=	M135SlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF3M{iwNlA5Lz5zNUO4NFIxQDxxYU6=
MCF7	MWrGeY5kfGmxbjDhd5NigQ>?			M3[3d2lvcGmkaYTpc44hd2ZiZYP0do9o\W5vaX7keYNm\CCycn;sbYZmemG2aX;uJIlvKGi3bXHuJG1ETi15IHLy[YF{fCClYX7j[ZIh[2WubIOsJGlEPTBiPTCwMlAxOTF5IN88UU4>	M4fC[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzlzNUS5OlMoRjlzNUS5OlM9N2F-
MCF7	NHnoXHpHfW6ldHnvckBie3OjeR?=		MniyNlQhcHK\|	Mn;3RY51[WexbnnzeEBi[3Srdnn0fUBifCCHUnHsdIhiKGmwIHj1cYFvKE2FRkegZ4VtdHNiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iCnc4Tyc4dmdi2rbnT1Z4VlKHS{YX7zZ5JqeHSrb36gdJJmcW6ldXLheIVlKG:4ZYLubYdpfCCob3zsc5dm\CCkeTDld5Rzd2enbjDh[IRqfGmxbjDt[YF{fXKnZDDh[pRmeiB{NDDodpMh[nliZIXhcEBtfWOrZnXyZZNmKHKncH;yeIVzKGenbnWgZZN{[XluIFnDOVAhRSByLkCwN{DPxE1w	NFHWZZo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEK5OlM6QCd-MkiyPVY{QTh:L3G+
Rosetta 2 DE3	NIGxcGZHfW6ldHnvckBie3OjeR?=		MXKxJIhz	MoDiSIl{eGyjY3Xt[Y51KG:oIGuzTH0u\XO2cnHkbY9tKG[{b32gdoVkd22kaX7hcpQhcHWvYX6gUk11\XKvaX7hcEBJcXNvdHHn[4VlKEWUYXzwbIEhVEKGIHjhdoJwemmwZzDDN\|gyWy:FNEG3V{9EPTNyUzDteZRidnRiZYjwdoV{e2WmIHnuJHJwe2W2dHGgNkBFTTNiY3;tdIV1\W62IHPlcIx{KGGodHXyJFEhcHJiYomgV3BCKGKrbnTpcoch[XO\|YYmsJGlEPTBiPTCwMlAxPCEQvF2u	NHPLcGc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEK5OlM6QCd-MkiyPVY{QTh:L3G+
insect cells	NVXFXFU1TnWwY4Tpc44h[XO\|YYm=			NU\iOXpvUW6qaXLpeIlwdiCxZjDmcJVwem2xbnWgSXMzKGe{ZXXuJIJqdmSrbnegeI8hemWlb33ibY5idnRiZoXscEBt\W6pdHigbJVu[W5iRWLhcJBp[SCneIDy[ZN{\WRiaX6gbY5{\WO2IHPlcIx{KGK7IH\seY9z\XOlZX7j[UBxd2yjcnn6ZZRqd25iYYPzZZktKEmFNUCgQUAxNjByNkK5JO69VS5?	MlvoQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh5M{WyNVQoRjJ6N{O1NlE1RC:jPh?=
MCF-7-2a	NYmydHYzTnWwY4Tpc44h[XO\|YYm=			M3HlV2lvcGmkaYTpc44hd2ZiZYP0doFlcW:uIHnu[JVk\WRiZYP0do9o\W5icnXj[ZB1d3JidILhcpNkemmydHnvcoFtKGGldHn2ZZRqd25iaX6gUWNHNTdvMnGgZ4VtdHNuIFnDOVAhRSByLkCwO{DPxE1w	NWXOXnVPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUK2O\|IzPDlpPkGyOlczOjR7PD;hQi=>
MCF7	NIizc\|FCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		MojBNlQhcHK\|	MWrBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE2FRkegZ4VtdHNiYX\0[ZIhOjRiaILzJIJ6KE2WUzDhd5NigSxiSVO1NEA:KDBwMEC4OUDPxE1w	NHnkR\|M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEK3NlI2Pid-MUiyO\|IzPTZ:L3G+
MCF7	MWrGeY5kfGmxbjDhd5NigQ>?			MVLJcohq[mm2b4L5JINwdmOnboTyZZRqd25iYXfhbY5{fCCPQ1[tO{BjemWjc4SgeJVud3JiY3XscJMhfXOrbnegUWNHNTdiYYPzZZktKEmFNUCgQUAxNjByOEWg{txONg>?	NFXnPWw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zMkiyOVk{PSd-MUK4NlU6OzV:L3G+
Ishikawa cells	NHvwcHRHfW6ldHnvckBie3OjeR?=		MYi3NkBpenN?	NIX2NpFCdnSjZ3;ubZN1KGGldHn2bZR6KGG2IHXzeJJw\2WwIILlZ4VxfG:{IHHsdIhiN2KndHGgbY4hcHWvYX6gTZNpcWujd3GgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KGGua3HsbY5mKHCqb4PwbIF1[XOnIHHzd4F6NCCLQ{WwJF0hOC5yMTFOwG0v	NV7lXFJqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki0NlY6OzFpPkK4OFI3QTNzPD;hQi=>
insect cells	M4np[WZ2dmO2aX;uJIF{e2G7			MW\EbZNxdGGlZX3lcpQhd2ZiZnz1c5Jme2OnaX6gcIFj\WynZDDld5Rz[WSrb3yg[pJwdSCqdX3hckBz\WOxbXLpcoFvfCCHUnLleIEh\XiycnXzd4VlKGmwIHLhZ5Vtd3[rcoXzJIlv\mWldHXkJIlve2WldDDj[YxteyCkeTDmcJVwemW\|Y3XuZ4UheG:uYYLpfoF1cW:wIHHzd4F6NCCLQ{WwJF0hOC5yMjFOwG0v	NX\lXVJtRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi4N\|UyPzZpPkG4PFM2OTd4PD;hQi=>
MCF7	MULDfZRwfG:6aXPpeJkh[XO\|YYm=		M{e3PVUh\GG7cx?=	NIDYPGdEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBOS0Z5IHPlcIx{KGGodHXyJFUh\GG7czygTWM2OCB;IECuNFI6OSEQvF2u	M1jXb\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OE[0PVI5Lz5{M{i2OFkzQDxxYU6=
GT1-7	M2X3b2Z2dmO2aX;uJIF{e2G7		MkXCNlAhfG9iMkSgbJJ{	NXPIRlV7SW62YXfvcol{fCCjY4Tpeol1gSCjdDDld5Rzd2enbjDy[YNmeHSxcjDpckBud3W\|ZTDHWFEuPyClZXzsd{Bp[XKkb4Lpcoch[mW2YT3nZYxi[3Sxc3nkZZNmKHKncH;yeIVzKGenbnWgZZN{\XO\|ZXSgZZMhemWmdXP0bY9vKGmwIEG3ZoV1[S2nc4TyZYRqd2xiaX7keYNm\CC{ZYPwc45{\SCvZXHzeZJm\CCjZoTldkAzOCC2bzCyOEBpenNiYomgcJVkcW[ncnHz[UBz\XCxcoTldkBo\W6nIHHzd4F6NCCLQ{WwJF0hOC5yM{OyJO69VS5?	NH3WT\|I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OESwNFI{QSd-Mki0NFAzOzl:L3G+
insect cells	NIXCSodHfW6ldHnvckBie3OjeR?=			MlzNSIl{eGyjY3Xt[Y51KG:oIH\seY9z\XOlZXnuJIxi[mWuZXSg[ZN1emGmaX;sJIZzd21iaIXtZY4hemWlb33ibY5idnRiRWLhcJBp[SCneIDy[ZN{\WRiaX6gZoFkfWyxdnnyeZMhcW6oZXP0[YQhcW6\|ZXP0JINmdGy\|IHL5JIZtfW:{ZYPj[Y5k\SCyb3zhdol7[XSrb36gZZN{[XluIFnDOVAhRSByLkC0JO69VS5?	NF3j[G09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEizOVE4Pid-MUi4N\|UyPzZ:L3G+
HEK293	NHvxUlFHfW6ldHnvckBie3OjeR?=		NXfTPHJmOzBibXnudy=>	NHTvVoNKdmirYnn0bY9vKG:oIFfGVE11[WepZXSgbJVu[W5iUFzENkBmgHC{ZYPz[YQhcW5iaIXtZY4hUEWNMkmzJINmdGy\|IHHzd4V{e2WmIHHzJIRm[3KnYYPlJIlvKHCqb4PwbIF1cWS7bHL1eIFvd2xvW3S5YUBxem:mdXP0bY9vKGGodHXyJFMxKG2rboOgZpkhdWG\|czDzdIVkfHKxbXX0dolkKGGwYXz5d4l{NCCLQ{WwJF0hOC5yNESg{txONg>?	MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTF\|Nkm3OUc,OTlzM{[5O\|U9N2F-
HEK293	M2jxXGZ2dmO2aX;uJIF{e2G7		NXW3No1YOSCqch?=	NFjZWmFCdnSjZ3;ubZN1KGGldHn2bZR6KGG2IILlZ49u[mmwYX70JIh2dWGwIFXSZYxxcGFiZYjwdoV{e2WmIHnuJGhGUzJ7MzDj[YxteyCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKGW\|dILh[IlwdC2rbnT1Z4VlKFmIUD3meZNm\CCVUlOxJINw[WO2aY\heI9zKHKnY4L1bZRu\W62IH3lZZN2emWmIHHmeIVzKDFiaIKgbY4heHKnc3XuZ4Uhd2ZiQ3;lcIVvfGW{YYrpcoUhUCCkeTDCVmVVKGG\|c3H5MEBKSzVyIE2gNE4xPyEQvF2u	NFrVPFc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9\|MEC3PFYxQSd-M{CwO\|g3ODl:L3G+
MCF7	NXPzVZprSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		M4Xt[VczKGi{cx?=	MYfBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHXzeJJw\2WwIILlZ4VxfG:{IHTldIVv\GWwdDDoeY1idiCPQ1[3JINmdGy\|IHHmeIVzKDd{IHjyd{BjgSCPVGSgZZN{[XluIFnDOVAhRSByLkGwO{DPxE1w	M3jEOlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6OEO1NVc3Lz5zOEizOVE4PjxxYU6=
MCF7	Mk\ERY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		MV[3NkBpenN?	M1\iSGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTVPGO{Bk\WyuczDh[pRmeiB5MjDodpMh[nlidIL5dIFvKGKudXWgZZN{[XluIFfJOVAhRSByLkGwO{DPxE1w	NYTDd29HRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO3N\|U5OjlpPkKzO\|M2QDJ7PD;hQi=>
MCF7	NX;VWm81SW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		M1S0eVczKGi{cx?=	NVvVTYJxSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBGWi2mZYDlcoRmdnRiaIXtZY4hVUOINzDj[YxteyCjZoTldkA4OiCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwJF0hOC5zMTFOwG0v	NUXpbXRjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki0NlY6OzFpPkK4OFI3QTNzPD;hQi=>
T47D	MVrDfZRwfG:6aXPpeJkh[XO\|YYm=		NVj3epdpPSCmYYnz	NGnRTm9EgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBVPDeGIHPlcIx{KGGodHXyJFUh\GG7czygTWM2OCB;IECuNlEh\|ryPLh?=	NHvKTXU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i2OFkzQCd-MkO4OlQ6Ojh:L3G+
Ishikawa endometrial cells	NWXiRVRSTnWwY4Tpc44h[XO\|YYm=			NXz2cIFuSW62YXfvcol{fCCjY4Tpeol1gSCjczDpcohq[mm2aX;uJI9nKDFibl2gNVcu[mW2YT3ld5Rz[WSrb3ygd5RqdXWuYYTl[EBidGujbHnu[UBxcG:\|cHjheIF{\SCrbnT1Z5Rqd25iaX6gTZNpcWujd3Gg[Y5ld22ndILpZYwh[2WubIOsJGlEPTBiPTCwMlUyKM7:TT6=	NUjROFVkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUWzPFAzODhpPkG1N\|gxOjB6PD;hQi=>
CV1	M{XqTmZ2dmO2aX;uJIF{e2G7		MoX6OFUhcHK\|	M4fv[mlvfmW{c3WgZYdwdmm\|dDDhZ5Rqfmm2eTDheEBISUx2LVTORUBjcW6maX7nJIRwdWGrbj3meZNm\CCvb4Xz[UBGWlKpYX3tZUBtcWejbnSgZolv\GmwZzDkc41icW5iZYjwdoV{e2WmIHnuJGFnemmlYX6g[5Jm\W5ibX;ub4V6KEOYMTDj[YxteyCjc4Pld5Nm\CCjczDk[YNz\WG\|ZTDpckBz\WOncITvdkB1emGwc3PybZB1cW:wYXygZYN1cX[rdImgZYZ1\XJiNEWgbJJ{KGK7IHz1Z4ln\XKjc3WgdoVxd3K2ZYKg[4Vv\SCjc4PhfUwhUUN3MDC9JFAvPiEQvF2u	M1fjZ\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MUi5N\|k{Lz5{OEG4PVM6OzxxYU6=
CV1	NFzSdJdHfW6ldHnvckBie3OjeR?=		NXixTY8yPDViaILz	NUHiV5o2UW64ZYLz[UBi\2:waYP0JIFkfGm4aYT5JIF1KEeDTEStSG5CKGKrbnTpcoch\G:vYXnuMYZ2e2WmIHj1cYFvKEWUUnLleIEhdGmpYX7kJIJqdmSrbneg[I9u[WmwIHX4dJJme3OnZDDpckBC\nKrY3HuJIdz\WWwIH3vcotmgSCFVkGgZ4VtdHNiYYPz[ZN{\WRiYYOg[IVkemWjc3WgbY4hemWlZYD0c5IhfHKjboPjdolxfGmxbnHsJIFkfGm4aYT5JIFnfGW{IES1JIhzeyCkeTDseYNq\mW{YYPlJJJmeG:{dHXyJIdmdmViYYPzZZktKEmFNUCgQUAxNjZ3IN88UU4>	M1rXWFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MUi5N\|k{Lz5{OEG4PVM6OzxxYU6=
HEK293	Mm[3SpVv[3Srb36gZZN{[Xl?			Ml7jRYdwdmm\|dDDhZ5Rqfmm2eTDheEBpfW2jbjDld5Rzd2enbjDy[YxifGWmIILlZ4VxfG:{IHfhcY1iKGW6cILld5Nm\CCrbjDISWszQTNiY3XscJMh[nlibIXjbYZmemG\|ZTDy[ZBwenSncjDn[Y5mKGG\|c3H5MEBKSzVyIE2gNU4{PSEQvF2u	NF[3WlE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUOwOVY5QCd-MkWzNFU3QDh:L3G+
MCF7	NXXrco5vSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		Mn\WOFghcHK\|	NEHyPWxCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF3DSlch[2WubIOg[ZhxemW\|c3nu[{Bme3S{b3flckBz\WOncITvdkBqdmO3YnH0[YQhf2m2aDCwMlAxOyCwTTDv[kBme3S{YXTpc4wh[W6mIECuNFEhdk1ib3[geIV{fG:\|dHXyc45mKGGodHXyJFQ5KGi{czDifUB{fWyob4Loc4RidWmwZTDCJIF{e2G7IHnuJJBz\XOnbnPlJI9nKDVnIH\leIFtKGKxdnnu[UB{\XK3bTygS2k2OCB;IEGuOFEzPTRizszNMi=>	M2qxTVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzNUGzNlc2Lz5{MUWxN\|I4PTxxYU6=
MCF7	NWHhPWZxSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		MUm0PEBpenN?	NVexUHZJSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDNR2Y4KGOnbHzzJIV5eHKnc4Ppcoch\XO2cn;n[Y4hemWlZYD0c5IhcW6ldXLheIVlKHerdHigNE4xPiCwTTDv[kBme3S{YXTpc4wh[W6mIECuNFchdk1ib3[geIV{fG:\|dHXyc45mKGGodHXyJFQ5KGi{czDifUB{fWyob4Loc4RidWmwZTDCJIF{e2G7IHnuJJBz\XOnbnPlJI9nKG[ndHHsJIJwfmmwZTDz[ZJ2dSCjbnSgUpVU\XK3bTygS2k2OCB;IEGuPVA2PDZizszNMi=>	MmjUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF3MUOyO\|UoRjJzNUGzNlc2RC:jPh?=
HeLa	NGf0[ItHfW6ldHnvckBie3OjeR?=		NUGxTGJVPC53IHjydy=>	MYLJcohq[mm2aX;uJI9nKEWkb3zheolzfXNiZ3z5Z49xem:2ZXnuM41ifHKreDDwdo91\WmwIG\QOFAh\W62comgbY4hcHWvYX6gTIVN[SClZXzsd{Bi\nSncjC0MlUhcHK\|IHLleIEudGGldHHtZZNmKHKncH;yeIVzKGG\|c3H5MEBKSzVyIE2gNU46PiEQvF2u	MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTZ{NEO4O{c,Ojl4MkSzPFc9N2F-
MDA-MB-231	MkfpR5l1d3SxeHnjbZR6KGG\|c3H5		NHnES5k1KGSjeYO=	MUfDfZRwfG:6aXPpeJkh[WejaX7zeEBGWiCwZXfheIl3\SCqdX3hckBOTEFvTVKtNlMyKGOnbHzzJJRz\WG2ZXSg[ZZmenliMjDkZZl{KG[xcjC0JIRigXNibXXhd5Vz\WRiYX\0[ZIhPyCmYYnzJIJ6KEOnbHzUbZRmei2JbH:gcJVucW6nc3PlcoNmKGG\|c3H5MEBKSzVyIE2gNk42KM7:TT6=	M{\KW\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyMEe4OlA6Lz5\|MEC3PFYxQTxxYU6=
MCF7	MmXNRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?			MmfxRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCPQ1[3JINmdGy\|IHHzd4V{e2WmIHHzJIlv[2:{cH;yZZRqd25ib3[gX41mfGi7bD2zTH11cHmvaXTpcoUhcW62bzDj[YxtfWyjcjDEUmEhcW5ic3XyeY0h\nKnZTDt[YRqfW1iaX6gbY4h[WK\|ZX7j[UBw\iB4LkKgeYcwdUxiUl7hd4UhOSxiSVO1NEA:KDJwNzFOwG0v	MkLaQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ4MUG0O\|goRjJ{NkGxOFc5RC:jPh?=
MCF7	MlnCRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		MXG3NkBpenN?	NUH0OHdmSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDNR2Y4KGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO\|YYmsJGlEPTBiPTCyMlc6KM7:TT6=	NGiwZnM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Nki5OlcxPid-Mk[4PVY4ODZ:L3G+
MCF12A	MVHBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		MoL5OFghcHK\|	NXS1UFYySW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBme3S{b3flckBz\WOncITvdk1l\W[rY3nlcpQhcHWvYX6gUWNHOTKDIHPlcIx{KGmwY4XiZZRm\CC5aYToJFExOCCwTTDv[kBme3S{YXTpc4wh[W6mIECuNFchdk1ib3[geIV{fG:\|dHXyc45mKGGodHXyJFQ5KGi{czDifUB{fWyob4Loc4RidWmwZTDCJIF{e2G7IHnuJJBz\XOnbnPlJI9nKG[ndHHsJIJwfmmwZTDz[ZJ2dSCjbnSgUpVU\XK3bTygS2k2OCB;IEOuNlM2QTRizszNMi=>	NEHn[3Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUWxN\|I4PSd-MkG1NVMzPzV:L3G+
MCF7	M{DTcWN6fG:2b4jpZ4l1gSCjc4PhfS=>		NXHMSGlpPCCmYYnz	MUXDfZRwfG:6aXPpeJkh[WejaX7zeEBGWiCyb4PpeIl3\SCqdX3hckBOS0Z5IHPlcIx{KHS{ZXH0[YQh\X[ncomgNkBl[Xm\|IH\vdkA1KGSjeYOgcYVie3W{ZXSgZYZ1\XJiNzDkZZl{KGK7IFPlcIxVcXSncj3HcI8hdHWvaX7ld4NmdmOnIHHzd4F6NCCLQ{WwJF0hOy5\|IN88UU4>	MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODB5OE[wPUc,OzByN{i2NFk9N2F-
MCF12A	NE\vW4VCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		MXS0PEBpenN?	NY\jV244SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBme3S{b3flckBz\WOncITvdk1l\W[rY3nlcpQhcHWvYX6gUWNHOTKDIHPlcIx{KGmwY4XiZZRm\CC5aYToJFAvODB\|IH7NJI9nKGW\|dILh[IlwdCCjbnSgNE4xOSCwTTDv[kB1\XO2b4P0[ZJwdmViYX\0[ZIhPDhiaILzJIJ6KHO3bH\vdohw\GGvaX7lJGIh[XO\|YYmgbY4heHKnc3XuZ4Uhd2ZiNTWg[oV1[WxiYn;2bY5mKHOncoXtMEBIUTVyIE2gN{4{OTF\|MTFOwG0v	M1PKeFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzNUGzNlc2Lz5{MUWxN\|I4PTxxYU6=
MCF7	NGjsTlVCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		MYC0PEBpenN?	M1TYbGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTVPGO{Bk\WyuczDlfJBz\XO\|aX7nJIV{fHKxZ3XuJJJm[2WydH;yJIlv[3WkYYTl[EB4cXSqIEGwNEBvVSCxZjDld5Rz[WSrb3ygZY5lKDBwMEegcm0hd2ZidHXzeI9{fGW{b37lJIFnfGW{IES4JIhzeyCkeTDzeYxnd3Kqb3ThcYlv\SCEIHHzd4F6KGmwIIDy[ZNmdmOnIH;mJIZmfGGuIHLveolv\SC\|ZYL1cUBidmRiToXT[ZJ2dSxiR1m1NEA:KDNwNE[3N\|ch\|ryPLh?=	MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTVzM{K3OUc,OjF3MUOyO\|U9N2F-
MDA-MB-231	MXnDfZRwfG:6aXPpeJkh[XO\|YYm=		MnnnOEBl[Xm\|	NWXBcJM1S3m2b4TvfIlkcXS7IHHnZYlve3RiRWKgcoVo[XSrdnWgbJVu[W5iTVTBMW1DNTJ\|MTDj[YxteyC2cnXheIVlKGW4ZYL5JFIh\GG7czDmc5IhPCCmYYnzJI1m[XO3cnXkJJBwe3RibHHzeEBld3OnIHL5JGNmdGyWaYTldk1IdG9ibIXtbY5me2OnbnPlJIF{e2G7LDDJR\|UxKD1iMz61JO69VS5?	NIHCd5M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9\|MEC3PFYxQSd-M{CwO\|g3ODl:L3G+
MCF12A	NHLXNZpCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		MlvtOFghcHK\|	Mkf1RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDld5Rzd2enbjDy[YNmeHSxcj3k[YZq[2mnboSgbJVu[W5iTVPGNVJCKGOnbHzzJIlv[3WkYYTl[EB4cXSqIECuNFYhdk1ib3[g[ZN1emGmaX;sJIFv\CByLkC3JI5OKG:oIITld5Rwe3Sncn;u[UBi\nSncjC0PEBpenNiYomgd5Vt\m:{aH;kZY1qdmViQjDhd5NigSCrbjDwdoV{\W6lZTDv[kBn\XSjbDDic5ZqdmVic3XyeY0h[W6mIF71V4VzfW1uIFfJOVAhRSB\|Lki5NFQ2KM7:TT6=	M1\LUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzNUGzNlc2Lz5{MUWxN\|I4PTxxYU6=
MCF7	M1jZOmN6fG:2b4jpZ4l1gSCjc4PhfS=>		MUi0JIRigXN?	NXXIVZZtS3m2b4TvfIlkcXS7IHHnZYlve3RiRWKgdI9{cXSrdnWgbJVu[W5iTVPGO{Bk\WyuczD0doVifGWmIHX2[ZJ6KDJiZHH5d{Bnd3JiNDDkZZl{KG2nYYP1doVlKHCxc4SgcIF{fCCmb4PlJIJ6KEOnbHzUbZRmei2JbH:gcJVucW6nc3PlcoNmKGG\|c3H5MEBKSzVyIE2gN{46KM7:TT6=	MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODB5OE[wPUc,OzByN{i2NFk9N2F-
MCF7	NEjtU\|VHfW6ldHnvckBie3OjeR?=			NF35fVFKdmirYnn0c5J6KGGldHn2bZR6KGGpYXnud5QheHKxbHnm[ZJifGmxbjDv[kBOS0ZvNzDj[YxteyCrbjDwdoV{\W6lZTDv[kAyOGVvNjDNJINwdmOnboTyZZRqd25ib3[gX\|NJZS1iZYP0doFlcW:uIDjFNkktKEmFM{CgQUA1KM7:TT6=	M3v4c\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5Nkm2PFEoRjJ5Nkm2PFE9N2F-
MCF10A	NET1S2hEgXSxdH;4bYNqfHliYYPzZZk>		M37GZ\|Qh\GG7cx?=	NYeyVpBiS3m2b4TvfIlkcXS7IHHnZYlve3RiRWKgcoVo[XSrdnWgbJVu[W5iTVPGNVBCKGOnbHzzJJRz\WG2ZXSg[ZZmenliMjDkZZl{KG[xcjC0JIRigXNibXXhd5Vz\WRicH;zeEBt[XO2IHTvd4Uh[nliQ3XscHRqfGW{LVfsc{BtfW2rbnXzZ4Vv[2ViYYPzZZktKEmFNUCgQUA1KM7:TT6=	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODB5OE[wPUc,OzByN{i2NFk9N2F-
MCF10A	NEXwU5hEgXSxdH;4bYNqfHliYYPzZZk>		NH74Vpk1KGSjeYO=	MXrDfZRwfG:6aXPpeJkh[WejaX7zeEBGWiCwZXfheIl3\SCqdX3hckBOS0ZzMFGgZ4VtdHNidILlZZRm\CCndnXyfUAzKGSjeYOg[o9zKDRiZHH5d{Bu\WG\|dYLl[EBi\nSncjC3JIRigXNiYomgR4VtdFSrdHXyMWdtdyCudX3pcoV{[2WwY3WgZZN{[XluIFnDOVAhRSB2IN88UU4>	NYTPeIcxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CwO\|g3ODlpPkOwNFc5PjB7PD;hQi=>
yeast cells	M4D1Z2FvfGmnc4Tyc4dmdmmlIHHzd4F6			M4\Pe2FvfGmnc4Tyc4dmdmmlIHHjeIl3cXS7IHH0JIV{fHKxZ3XuJJJm[2WydH;yJIFteGijIHX4dJJme3OnZDDpckB6\WG\|dDDj[YxteyCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKDF5LXLleIEu\XO2cnHkbY9tNWmwZIXj[YQh[mW2YT3nZYxi[3Sxc3nkZZNmKGGldHn2bZR6KGK7IIT3c{BpgWK{aXSgZZN{[XluIFnDOVAhRSB2LkSg{txONg>?	NWjaS5ZZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMU[0OFExQDZpPkG2OFQyODh4PD;hQi=>
NCI-ADR-RES	NUnFXW1{SW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		Mn;JOFghcHK\|	MWfBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHXzeJJw\2WwIILlZ4VxfG:{LXTl[olkcWWwdDDoeY1idiCQQ1mtRWRTNVKHUzDj[YxteyCrbnP1ZoF1\WRid3n0bEAxNjByMzDuUUBw\iCnc4TyZYRqd2xiYX7kJFAvODFibl2gc4YhfGW\|dH;zeIVzd26nIHHmeIVzKDR6IHjyd{BjgSC\|dXzmc5Jpd2SjbXnu[UBDKGG\|c3H5JIlvKHC{ZYPlcoNmKG:oIEWlJIZmfGGuIHLveolv\SC\|ZYL1cUwhT0l3MDC9JFQvPDZ4OESg{txONg>?	M2CyWFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzNUGzNlc2Lz5{MUWxN\|I4PTxxYU6=
BT-20	MkLBSpVv[3Srb36gZZN{[Xl?	NHrGU4gyOCEQvF2=		NF;JZoVKdmirYnn0c5J6KGGldHn2bZR6KGGpYXnud5QheHKxbHnm[ZJifGmxbjDv[kBDXC1{MDDj[YxteyCrbjDwdoV{\W6lZTDv[kBVWEViYYSgNVBmNTViTTDjc45k\W62cnH0bY9vNCCLQ{OwJF0hPC56IN88UU4>	NVvSc2RPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke2PVY5OSd-Mke2PVY5OTxxYU6=
Calu-1	MoTRSpVv[3Srb36gZZN{[Xl?		NIXnXIk{OCCvaX7z	NIjZe2NKdmirYnn0bY9vKG:oIGDMSFEhcW5iaIXtZY4hS2GudT2xJINmdGy\|IHHzd4V{e2WmIHHzJIRm[3KnYYPlJIlvKHCqb4PwbIF1cWS7bHL1eIFvd2xvW3S5YUBxem:mdXP0bY9vKGGodHXyJFMxKG2rboOgZpkhdWG\|czDzdIVkfHKxbXX0dolkKGGwYXz5d4l{NCCLQ{WwJF0hPC56IN88UU4>	M2LTWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7MUO2PVc2Lz5zOUGzOlk4PTxxYU6=
MCF7	NYO4WFBTTnWwY4Tpc44h[XO\|YYm=			MWfBcpRi\2:waYP0JIFkfGm4aYT5JIF1KEWUYXzwbIEhemWlZYD0c5IhcW5iaIXtZY4hVUOINzDj[YxteyxiSVO1NEA:KDRwOEm3O\|kh\|ryPLh?=	NIm2Z5I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkSwO\|AyOid-Mk[0NFcxOTJ:L3G+
MDA-MB-231	M2HoWGFvfGmlYX7j[ZIh[XO\|YYm=		Mnr2OFghcHK\|	Mnz3RY51cWOjbnPldkBi\2GrboP0JIh2dWGwIFXSMZBwe2m2aY\lJG1FSS2PQj2yN\|Eh[2WubIOgZZN{\XO\|ZXSgZZMh[2WubDD2bYFjcWyrdImgZYZ1\XJiNEigbJJ{KGK7IGPSRkBie3OjeTygTWM2OCB;IEWuOEDPxE1w	NIW4dpQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEm0OlE1PSd-MkS5OFYyPDV:L3G+
MCF-7	MXzDfZRwfG:6aXPpeJkh[XO\|YYm=			M1ryXWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KE2FRj23JINmdGy\|IHnuJJRp\SCjYoPlcoNmKG:oIEGgeW0hTTJiKHXzeJJi\GmxbDmsJGN6fG:2b4jpZ4l1gSB;IE[g{txONg>?	MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek86ODh7M{OyK\|46ODh7M{OyQE9iRg>?
NCI-ADR-RES	NH\ie3JCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		NEXmXVI1QCCqcoO=	NVzHdHhbSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBme3S{b3flckBz\WOncITvdk1l\W[rY3nlcpQhcHWvYX6gUmNKNUGGUj3SSXMh[2WubIOgbY5kfWKjdHXkJJdqfGhiMD6wOkBvVSCxZjDld5Rz[WSrb3ygZY5lKDBwMEegcm0hd2ZidHXzeI9{fGW{b37lJIFnfGW{IES4JIhzeyCkeTDzeYxnd3Kqb3ThcYlv\SCEIHHzd4F6KGmwIIDy[ZNmdmOnIH;mJIZmfGGuIHLveolv\SC\|ZYL1cUBidmRiToXT[ZJ2dSxiR1m1NEA:KDZwMU[1PVUh\|ryPLh?=	Mlv1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF3MUOyO\|UoRjJzNUGzNlc2RC:jPh?=
AU565	MVnBcpRq[2GwY3XyJIF{e2G7		MkXsOFghcHK\|	NVfwT\|ZiSW62aXPhcoNmeiCjZ3HpcpN1KGi3bXHuJGVTNW6nZ3H0bZZmKEGXNU[1JINmdGy\|IHHzd4V{e2WmIHHzJINmdGxidnnhZoltcXS7IHHmeIVzKDR6IHjyd{BjgSCVUlKgZZN{[XluIFnDOVAhRSB4LkKg{txONg>?	MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDl2NkG0OUc,OjR7NE[xOFU9N2F-
MCF7L	NFjsb2RCdnSrY3HuZ4VzKGG\|c3H5		Mn7IOFghcHK\|	MnnVRY51cWOjbnPldkBi\2GrboP0JIh2dWGwIFXSMZBwe2m2aY\lJG1ETjeOIHPlcIx{KGG\|c3Xzd4VlKGG\|IHPlcIwhfmmjYnnsbZR6KGGodHXyJFQ5KGi{czDifUBUWkJiYYPzZZktKEmFNUCgQUA3NjNizszNMi=>	Mn;GQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7NE[xOFUoRjJ2OUS2NVQ2RC:jPh?=
SKOV3-MDR1-M6/6	NIHnWXNCdnSrY3HuZ4VzKGG\|c3H5		NITNTpA1QCCqcoO=	MWTBcpRq[2GwY3XyJIFo[Wmwc4SgbJVu[W5iU1vPWlMuVUSUMT3NOk83KGOnbHzzJIF{e2W\|c3XkJIF{KGOnbHygeoli[mmuaYT5JIFnfGW{IES4JIhzeyCkeTDTVmIh[XO\|YYmsJGlEPTBiPTC2MlQ6KM7:TT6=	MkT3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7NE[xOFUoRjJ2OUS2NVQ2RC:jPh?=
MCF7	M1flN2FvfGmycn;sbYZmemG2aY\lJIF{e2G7		NFzibIIzPCCqcoO=	Mn3tRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCPQ1[3JINmdGy\|IHHmeIVzKDJ2IHjyd{BjgSCPVGSgZZN{[XluIFnDOVAhRSB5LkKg{txONg>?	NV\1fIgzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSxPFkxPTVpPkK0NVg6ODV3PD;hQi=>
SKOV3	M17lZ2FvfGmlYX7j[ZIh[XO\|YYm=		MmfsOFghcHK\|	NEDlTmNCdnSrY3HuZ4VzKGGpYXnud5QhcHWvYX6gV2tQXjNiY3XscJMhd3[ncnX4dJJme3OrbnegVE1oeCCjc4Pld5Nm\CCjczDj[YxtKH[rYXLpcIl1gSCjZoTldkA1QCCqcoOgZpkhW1KEIHHzd4F6NCCLQ{WwJF0hPy52NjFOwG0v	MmHVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7NE[xOFUoRjJ2OUS2NVQ2RC:jPh?=
PC3	MkHrRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		MUe0PEBpenN?	MlPrRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDhcoRzd2enbjDy[YNmeHSxcj3k[YZq[2mnboSgbJVu[W5iUFOzJINmdGy\|IHnuZ5Vj[XSnZDD3bZRpKDBwNjDuUUBw\iCnc4TyZYRqd2xiYX7kJFAvPyCwTTDv[kB1\XO2b4P0[ZJwdmViYX\0[ZIhPDhiaILzJIJ6KHO3bH\vdohw\GGvaX7lJGIh[XO\|YYmsJGdKPTBiPTC3MlU5PTd6IN88UU4>	NUSwV3lYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG1NVMzPzVpPkKxOVE{Ojd3PD;hQi=>
NCI-ADR-RES	NFnGepRCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		NXm2Uo9EPDhiaILz	MUjBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHXzeJJw\2WwIILlZ4VxfG:{LXTl[olkcWWwdDDoeY1idiCQQ1mtRWRTNVKHUzDj[YxteyCrbnP1ZoF1\WRid3n0bEAyODBibl2gc4Yh\XO2cnHkbY9tKGGwZDCwMlA4KG6PIH;mJJRme3Sxc4Tldo9v\SCjZoTldkA1QCCqcoOgZpkhe3WuZn;ybI9l[W2rbnWgRkBie3OjeTDpckBxemW\|ZX7j[UBw\iCoZYThcEBjd3[rbnWgd4VzfW1iYX7kJG52W2W{dX2sJGdKPTBiPTC3Mlc3OjR5IN88UU4>	NYnQU5QyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG1NVMzPzVpPkKxOVE{Ojd3PD;hQi=>
MCF-7	MnzIR5l1d3SxeHnjbZR6KGG\|c3H5			M1:2[WN6fG:\|dHH0bYNqfHliYXfhbY5{fCCPQ1[tO{Bk\WyuczDpckB1cGVicILld4Vv[2Vib3[gNUB2VW:uYYKgSVIhMGW\|dILh[IlwdCluIFnDOVAhRSB6IN88UU4>	MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek86ODh7M{OyK\|46ODh7M{OyQE9iRg>?
LNCAP	MW\BcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		NUPlXZBtPDhiaILz	NELRemdCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFzOR2FRKGOnbHzzJIV5eHKnc4Ppcoch[W6mcn;n[Y4hemWlZYD0c5IhcW6ldXLheIVlKHerdHigNE43KG6PIH;mJIV{fHKjZHnvcEBidmRiMD63JI5OKG:oIITld5Rwe3Sncn;u[UBi\nSncjC0PEBpenNiYomgd5Vt\m:{aH;kZY1qdmViQjDhd5NigSxiR1m1NEA:KDhwM{G3OlQh\|ryPLh?=	M2\KXVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzNUGzNlc2Lz5{MUWxN\|I4PTxxYU6=
MCF7	MXfBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		MVG1JIRigXN?	M1zLN2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTVPGO{Bk\WyuczDh[pRmeiB3IHThfZMh[nliV2PUMVgh[XO\|YYmsJGlEPTBiPTC4Mlkh\|ryPLh?=	MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTZzNEGxPEc,OjV4MUSxNVg9N2F-
MCF7	NYTzUWdiSW62aXPhcoNmeiCjc4PhfS=>		M4L1VFQ5KGi{cx?=	MX;BcpRq[2GwY3XyJIFo[Wmwc4SgbJVu[W5iRWKtdI9{cXSrdnWgUWNHPyClZXzsd{Bie3Onc4Pl[EBieyClZXzsJJZq[WKrbHn0fUBi\nSncjC0PEBpenNiYomgV3JDKGG\|c3H5MEBKSzVyIE2gPU4zKM7:TT6=	MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDl2NkG0OUc,OjR7NE[xOFU9N2F-
MCF-7	MVvDfZRwfG:6aXPpeJkh[XO\|YYm=			NG\WZmREgXSxdH;4bYNqfHliYXfhbY5{fCCPQ1[tO{Bk\WyuczDpckBxemW\|ZX7j[UBw\iBzIIXNJGUzKCinc4TyZYRqd2xrLDDDfZRwfG:6aXPpeJkhRSB7LkSg{txONg>?	MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek86ODh7M{OyK\|46ODh7M{OyQE9iRg>?
MDA-MB-231	NEjJPVlCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		NX3LVXZ5OjRiaILz	M{nRbmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTVTBMW1DNTJ\|MTDj[YxteyCjZoTldkAzPCCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwJF0hOTBwNDFOwG0v	NWDRS2Z3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSxPFkxPTVpPkK0NVg6ODV3PD;hQi=>
MDA-MB-453	NGjVWXNCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		NID6emM4OiCqcoO=	MX7BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE2GQT3NRk01PTNiY3XscJMh[W[2ZYKgO\|IhcHK\|IHL5JG1VXCCjc4PhfUwhUUN3MDC9JFExNjRizszNMi=>	MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDVyNkW4Nkc,Ojh3ME[1PFI9N2F-
DU145	NEjER\|lCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		M3PLTFQ5KGi{cx?=	M2DIUmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgZY5lem:pZX6gdoVk\XC2b4Kt[IVncWOrZX70JIh2dWGwIFTVNVQ2KGOnbHzzJIlv[3WkYYTl[EB4cXSqIECuOkBvVSCxZjDld5Rz[WSrb3ygZY5lKDBwNzDuUUBw\iC2ZYP0c5N1\XKxbnWgZYZ1\XJiNEigbJJ{KGK7IIP1cIZwemixZHHtbY5mKEJiYYPzZZktKEeLNUCgQUAyOC55MUWyJO69VS5?	M{XRbVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzNUGzNlc2Lz5{MUWxN\|I4PTxxYU6=
MCF7	MWrDfZRwfG:6aXPpeJkh[XO\|YYm=		NXPWO\|g3PDhiaILz	NELOfGJEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBOS0Z5IHPlcIx{KGGodHXyJFQ5KGi{czDifUBOXFRiYYPzZZktKEmFNUCgQUAyOy54IN88UU4>	MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTZzOEW5OUc,OjV4MUi1PVU9N2F-
Vero	MX\BcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		NVzLXWR7PzJiaILz	MnnJRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDh[pJq[2GwIHfy[YVvKG2xbnvlfUBX\XKxIHPlcIx{KGG\|c3Xzd4VlKGG\|IHnubIljcXSrb36gc4Yh[2WubDD2bYFjcWyrdImgZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTygTWM2OCB;IEG1MlEh\|ryPLh?=	NYPxcmxyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW5PVMzPjlpPkK1PVk{OjZ7PD;hQi=>
DU145	NIfPU5VCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		NGK2UXA4OiCqcoO=	MYfBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKESXMUS1JINmdGy\|IHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZiY3XscEB3cWGkaXzpeJkh[W[2ZYKgO\|IhcHK\|IHL5JG1VXCCjc4PhfUwhUUN3MDC9JFE2NjNizszNMi=>	NIHhc2g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUm5N\|I3QSd-MkW5PVMzPjl:L3G+
MCF7	NYrxWVRUSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		M3j6RVczKGi{cx?=	MoTMRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCPQ1[3JINmdGy\|IHHmeIVzKDd{IHjyd{BjgSCPVGSgZZN{[XluIFnDOVAhRSBzNT62JO69VS5?	MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDVyNkW4Nkc,Ojh3ME[1PFI9N2F-
MCF7	MU\BcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		MmnpO\|IhcHK\|	MW\BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE2FRkegZ4VtdHNiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iClZXzsJJZq[WKrbHn0fUBi\nSncjC3NkBpenNiYomgUXRVKGG\|c3H5MEBKSzVyIE2gNVUvPiEQvF2u	NHmybHo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUm5N\|I3QSd-MkW5PVMzPjl:L3G+
MDA-MB-231	M4ThUGFvfGmycn;sbYZmemG2aY\lJIF{e2G7		MU[3NkBpenN?	MVTBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE2GQT3NRk0zOzFiY3XscJMh[W[2ZYKgO\|IhcHK\|IHL5JG1VXCCjc4PhfUwhUUN3MDC9JFIxNjFizszNMi=>	MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDVyNkW4Nkc,Ojh3ME[1PFI9N2F-
MCF7	NH;GNm9CdnSrcILvcIln\XKjdHn2[UBie3OjeR?=	NGizZncxNjZ{NTDuUS=>	Mne4NlQhcHK\|	MYTBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE2FRkegZ4VtdHNiYYSgNE43OjVibl2gZYZ1\XJiMkSgbJJ{KGK7IF3UV{Bie3OjeR?=	NYDWfHo3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUiyO\|IzPTZpPkG4NlczOjV4PD;hQi=>
MCF7	MnK1RY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?	MnHKNE43OjVidH:gNVAhdk1?	NX\vWWJSOjRiaILz	MlrmRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCPQ1[3JINmdGy\|IHH0JF4xNjZ{NTD0c{AyOCCwTTDh[pRmeiB{NDDodpMh[nliTWTTJIF{e2G7	NV\uXW96RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUiyO\|IzPTZpPkG4NlczOjV4PD;hQi=>
MCF7:WS8	M1LYSmZ2dmO2aX;uJIF{e2G7			NYfIOlhJSWO2aY\heIlwdiCxZjDoeY1idiCHUjDpckBpfW2jbjDNR2Y4QleVODDj[YxteyCneIDy[ZN{cW6pIHXzeJJw\2WwIILld5BwdnOrdnWg[YxmdWWwdDDifUBtfWOrZnXyZZNmKHKncH;yeIVzKGenbnWgZZN{[Xl?	NX3PTmRFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkCzN\|Q{PjhpPkKwN\|M1OzZ6PD;hQi=>
MCF7:WS8	M3HLfGFvfGmnc4Tyc4dmdmmlIHHzd4F6	MlHDNUB2VQ>?	Mlm0O{Bl[Xm\|	MWjBcpRq\XO2cn;n[Y5q[yCjY4Tpeol1gSCrbjDoeY1idiCHUnHsdIhiKGW6cILld5NqdmdiTVPGO\|pYWzhiY3XscJMh[XO\|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBme3S{YXTpc4wucW6mdXPl[EBxem:uaX\ldoF1cW:wIHH0JFEhfU1iYX\0[ZIhPyCmYYnz	NUPtbnRIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkCzN\|Q{PjhpPkKwN\|M1OzZ6PD;hQi=>
MCF7	NVLOSpVWSW62aXXzeJJw\2WwaXOgZZN{[Xl?			MXzBcpRq\XO2cn;n[Y5q[yCjY4Tpeol1gSCrbjDoeY1idiCPQ1[3JINmdGy\|IHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZiZYP0doFlcW:uLYP0bY12dGG2ZXSgdJJwdGGldHnuJIdmdmViZYjwdoV{e2mxbh?=	M{S2dlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyM{O0N\|Y5Lz5{MEOzOFM3QDxxYU6=
MCF7	MWjBcpRq\XO2cn;n[Y5q[yCjc4PhfS=>			MUXBcpRq\XO2cn;n[Y5q[yCjY4Tpeol1gSCrbjDoeY1idiCPQ1[3JINmdGy\|IHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZiZYP0doFlcW:uLYP0bY12dGG2ZXSgdJJwdGmoZYLheIlwdg>?	NH71dVY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEOzOFM3QCd-MkCzN\|Q{Pjh:L3G+
T47D:C:4:2	MXnGeY5kfGmxbjDhd5NigQ>?			M17aSmV{fHKxZ3XubYMh[WO2aY\peJkh[XRid3ns[EB1gXCnIFXSJIFteGijIHX4dJJme3OnZDDpckBVPDeGOlO6OFozKGOnbHzzJINw\XiycnXzd4lv\yCnc4Tyc4dmdiC{ZYPwc45{\SCnbHXt[Y51KGK7IHT1[YwhdHWlaX\ldoF{\SC{ZYDvdpRmeiCpZX7lJIF{e2G7	MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODN\|NEO2PEc,OjB\|M{SzOlg9N2F-
MDA-MB-231	M2rST2N6fG:2b4jpZ4l1gSCjc4PhfS=>		MW[zJIRigXN?	MliyR5l1d3O2YYTpZ{Bi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF3ERU1OSi1{M{GgZ4VtdHNiYX\0[ZIhOyCmYYnzJIJ6KG2rY4LveIl1\XJiYYPzZZk>	MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODV7OEW1OUc,OjB3OUi1OVU9N2F-
T47D:C:4:2	MXHGeY5kfGmxbjDhd5NigQ>?			NHzlTJJGe3S{b3flcolkKGGldHn2bZR6KGG2IIfpcIQhfHmyZTDFVkBidHCqYTDEN\|UyTyCvdYThcpQh\XiycnXzd4VlKGmwIGS0O2Q7Szp2OkKgZ4VtdHNiY3;lfJBz\XO\|aX7nJIV{fHKxZ3XuJJJme3CxboPlJIVt\W2nboSgZpkh\HWnbDDseYNq\mW{YYPlJJJmeG:{dHXyJIdmdmViYYPzZZk>	NHnONnE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEOzOFM3QCd-MkCzN\|Q{Pjh:L3G+
MCF7	Mn76SpVv[3Srb36gZZN{[Xl?	NEOweHYyKM7:TR?=	M1ToZlYh\GG7cx?=	NWG1UHM6THK3ZzD1dJRic2ViaX6gbJVu[W5iTVPGO{Bk\WyuczDheEAyOCdvNjDNJIFnfGW{IE[g[IF6eyCkeTDIVGxENU2VL13TJIFv[Wy7c3nz	NFrGd209[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i2OFkzQCd-MkO4OlQ6Ojh:L3G+
MCF7	NHjlNFJHfW6ldHnvckBie3OjeR?=	NEnhbmwyOCC3TR?=	NGjBSGk3KGi{cx?=	M{WxXnVxemWpdXzheIlwdiCxZjDFVoFteGijIIDyc5RmcW5ibHX2[Yx{KGmwIHj1cYFvKE2FRkegZ4VtdHNiYYSgNVAhfU1iYX\0[ZIhPiCqcoOgZpkhX2W\|dHXyckBjdG:2IH3leIhw\A>?	NHjn[3A9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEOzNlY{OCd-MkSzN\|I3OzB:L3G+
MCF7:WS8	MWrGeY5kfGmxbjDhd5NigQ>?	NGDWeYsyKM7:TR?=	NWHVPJNPPDhiaILz	NHS4S4NC\2:waYP0JIFkfGm4aYT5JIF1KEWUIHnuJIh2dWGwIF3DSlc7X1N6IHPlcIx{KGG\|c3Xzd4VlKGG\|IIDTNkBo\W6nIHX4dJJme3Orb36gZZQhOTBpLU[gUUBi\nSncjC0PEBpenNiYomgVnQuWEOUIHHuZYx6e2m\|	NYXn[nRORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4NFUyQTlpPkK0PFA2OTl7PD;hQi=>
MCF7:WS8	MmPPSpVv[3Srb36gZZN{[Xl?	NW\6cVdROSEQvF2=	M{LOeVQ5KGi{cx?=	M4HG[WFod26rc4SgZYN1cX[rdImgZZQhTVJiaX6gbJVu[W5iTVPGO\|pYWzhiY3XscJMh[XO\|ZYPz[YQh[XNiR2LFRlEh\2WwZTDlfJBz\XO\|aX;uJIF1KDFyJz22JG0h[W[2ZYKgOFghcHK\|IHL5JHJVNVCFUjDhcoFtgXOrcx?=	MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDhyNUG5PUc,OjR6MEWxPVk9N2F-
GH3	M3f6PWZ2dmO2aX;uJIF{e2G7	M4rMXVEh\|ryP	M2PSOFQ5KGi{cx?=	NWHu[Fh[SW62YXfvcol{fCCjY4Tpeol1gSCjdDDFVkBqdiC{YYSgS2g{KGOnbHzzJIF{e2W\|c3XkJIF{KGmwaHnibZRqd25ib3[g[ZN1emGmaX;sMYlv\HWlZXSgdJJwdGGldHnuJIdmdmViZYjwdoV{e2mxbjDheEAyOCdvNjDNJIFnfGW{IES4JIhzeyCkeTDSWE1RS1JiYX7hcJl{cXN?	NFHneZE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEiwOVE6QSd-MkS4NFUyQTl:L3G+
GH3	M4PKeGZ2dmO2aX;uJIF{e2G7	M1HXNFAvOSCwTTD0c{AyKM7:TR?=	NGLyWGQ1QCCqcoO=	NHHOcXFCdnSjZ3;ubZN1KGGldHn2bZR6KGG2IFXSJIlvKHKjdDDHTFMh[2WubIOgZZN{\XO\|ZXSgZZMhcW6qaXLpeIlwdiCxZjDld5Rz[WSrb3ytbY5lfWOnZDDwdo9t[WO2aX6g[4Vv\SCneIDy[ZN{cW:wIHH0JFExLy1zMDD0c{AyOCdvNjDNJIFnfGW{IES4JIhzeyCkeTDSWE1RS1JiYX7hcJl{cXN?	MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDhyNUG5PUc,OjR6MEWxPVk9N2F-
MCF7	NVm5dYl7SW62aXPhcoNmeiCjc4PhfS=>	Mo\XNlUxKHSxIEWwNEBvVQ>?	MV21JIRigXN?	NFWwT4JCdnSrY3HuZ4VzKGGpYXnud5QhcHWvYX6gSXIueG:\|aYTpeoUhVUOINzDj[YxteyCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKGW\|dILh[IlwdC2rbnT1Z4VlKGOnbHygdJJwdGmoZYLheIlwdiCjdDCyOVAhfG9iNUCwJI5OKGGodHXyJFUh\GG7cx?=	M{jXSlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUS2NVQ2Lz5{NEm0OlE1PTxxYU6=
MCF7	NVLJSndlTnWwY4Tpc44h[XO\|YYm=	MX61JJVO	NXj5U2VsOjRiaILz	MUfBcpRi\2:waYP0JIFkfGm4aYT5JIF1KEWUYXzwbIEhcW5iaIXtZY4hVUOINzDj[YxteyCjc4Pld5Nm\CCjczDzeZBxemW\|c3nvckBw\iCPWVOgcXJPSSCneIDy[ZN{cW:wIHH0JFUhfU1iYX\0[ZIhOjRiaILzJIJ6KFGLQYrvcEBz\WGpZX70JIJie2WmIGLUMZFRS1JiYX7hcJl{cXN?	MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODB5OE[wPUc,OzByN{i2NFk9N2F-
MCF7	NUG0UnM1TnWwY4Tpc44h[XO\|YYm=	NFHnUW42KHWP	MXKyOEBpenN?	NHq0NWhCdnSjZ3;ubZN1KGGldHn2bZR6KGG2IFXSZYxxcGFiaX6gbJVu[W5iTVPGO{Bk\WyuczDhd5Nme3OnZDDhd{B{fXCycnXzd4lwdiCxZjDUSmYyKG2UTlGg[ZhxemW\|c3nvckBifCB3IIXNJIFnfGW{IEK0JIhzeyCkeTDRTWF7d2xicnXh[4VvfCCkYYPl[EBTXC2zUFPSJIFv[Wy7c3nz	MkjLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzByN{i2NFkoRjNyMEe4OlA6RC:jPh?=
MCF7	NHXCdIlHfW6ldHnvckBie3OjeR?=	M2fK[lUhfU1?	NGLIVYszPCCqcoO=	NVHyN20ySW62YXfvcol{fCCjY4Tpeol1gSCjdDDFVoFteGijIHnuJIh2dWGwIF3DSlch[2WubIOgZZN{\XO\|ZXSgZZMhe3WycILld5Nqd25ib3[gS3JGSjFibWLORUBmgHC{ZYPzbY9vKGG2IEWgeW0h[W[2ZYKgNlQhcHK\|IHL5JHFKSXqxbDDy[YFo\W62IHLhd4VlKFKWLYHQR3Ih[W6jbInzbZM>	NXjyfVd6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CwO\|g3ODlpPkOwNFc5PjB7PD;hQi=>
MCF7	MUjGeY5kfGmxbjDhd5NigQ>?	NHfidXM2KHWP	MkDRNlQhcHK\|	M2PSRmFvfGGpb37pd5Qh[WO2aY\peJkh[XRiRWLhcJBp[SCrbjDoeY1idiCPQ1[3JINmdGy\|IHHzd4V{e2WmIHHzJJN2eHC{ZYPzbY9vKG:oIF3ZRmwzKG2UTlGg[ZhxemW\|c3nvckBifCB3IIXNJIFnfGW{IEK0JIhzeyCkeTDRTWF7d2xicnXh[4VvfCCkYYPl[EBTXC2zUFPSJIFv[Wy7c3nz	MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODB5OE[wPUc,OzByN{i2NFk9N2F-
MCF7	NEXjRZlHfW6ldHnvckBie3OjeR?=	NW\jNFBlPSC3TR?=	M1vB[VI1KGi{cx?=	Ml\GRY51[WexbnnzeEBi[3Srdnn0fUBifCCHUnHsdIhiKGmwIHj1cYFvKE2FRkegZ4VtdHNiYYPz[ZN{\WRiYYOgd5VxeHKnc4Ppc44hd2ZiQ1POSFEhdVKQQTDlfJBz\XO\|aX;uJIF1KDVidV2gZYZ1\XJiMkSgbJJ{KGK7IGHJRZpwdCC{ZXHn[Y51KGKjc3XkJHJVNXGSQ2KgZY5idHm\|aYO=	MkLpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzByN{i2NFkoRjNyMEe4OlA6RC:jPh?=
MCF7	MVfGeY5kfGmxbjDhd5NigQ>?	MXy1JJVO	MV2yOEBpenN?	NFWwPIdCdnSjZ3;ubZN1KGGldHn2bZR6KGG2IFXSZYxxcGFiaX6gbJVu[W5iTVPGO{Bk\WyuczDhd5Nme3OnZDDhd{B{fXCycnXzd4lwdiCxZjDDSGM3KG2UTlGg[ZhxemW\|c3nvckBifCB3IIXNJIFnfGW{IEK0JIhzeyCkeTDRTWF7d2xicnXh[4VvfCCkYYPl[EBTXC2zUFPSJIFv[Wy7c3nz	M4P5W\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyMEe4OlA6Lz5\|MEC3PFYxQTxxYU6=
MCF7	M2jkfmZ2dmO2aX;uJIF{e2G7	M3fLVFUhfU1?	NH7VfIkzPCCqcoO=	NW\OV2t5SW62YXfvcol{fCCjY4Tpeol1gSCjdDDFVoFteGijIHnuJIh2dWGwIF3DSlch[2WubIOgZZN{\XO\|ZXSgZZMhe3WycILld5Nqd25ib3[gSVJHOSCvUl7BJIV5eHKnc4Ppc44h[XRiNTD1UUBi\nSncjCyOEBpenNiYomgVWlCgm:uIILlZYdmdnRiYnHz[YQhWlRvcWDDVkBidmGueYPpdy=>	MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODB5OE[wPUc,OzByN{i2NFk9N2F-
MCF7	NVPQNlQ1TnWwY4Tpc44h[XO\|YYm=	NVzmU3NvPSC3TR?=	M4q5WVI1KGi{cx?=	M2\P[2FvfGGpb37pd5Qh[WO2aY\peJkh[XRiRWLhcJBp[SCrbjDoeY1idiCPQ1[3JINmdGy\|IHHzd4V{e2WmIHHzJJN2eHC{ZYPzbY9vKG:oIF3LTVY4KG2UTlGg[ZhxemW\|c3nvckBifCB3IIXNJIFnfGW{IEK0JIhzeyCkeTDRTWF7d2xicnXh[4VvfCCkYYPl[EBTXC2zUFPSJIFv[Wy7c3nz	NWTuZZR1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CwO\|g3ODlpPkOwNFc5PjB7PD;hQi=>

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	p-ERK / ERK / p-MEK / MEK1 / MEK2 / p21 / Cyclin D1 ; PubMed: 26163823 Cell Signal LNCaP-Raf:ER cells were treated with increasing doses of 4-hydroxytamoxifen for 2 days. The bottom panel indicates densitometry of MEK1 and MEK2 signals. Data (mean ± standard error) are from two independent experiments. Pearson’s r = 0.823 for MEK1 and −0.673 for MEK2.	26163823
Growth inhibition assay	Cell viability; PubMed: 26014809 Eur J Nutr Dose-dependent effect of 4-hydroxytamoxifen on survival of T47D, MCF-7 and BT-474 cell lines after 96 h of treatment. Control samples were treated with appropriate concentrations of DMSO. Viability was assayed by MTT method.	26014809

Protocol

Cell Research: ^[1]	- Collapse Cell lines: Adult Rat and Mouse Cardiac Myocytes Concentrations: 0, 0.5, 1, 3, 5, and 10 µM Incubation Time: 15-45 min Method: For sarcomere length measurements, cells are covered in Tyrode’s containing 4OHT, allowed to reach 36 ± 1°C, and then stimulated at 0.2 Hz. (Only for Reference)
Animal Research: ^[2]	- Collapse Animal Models: Sprague-Dawley rats Dosages: 21 mg/kg, 54 μmol/kg Administration: oral administration (Only for Reference)

References

Solubility (25°C)

In vitro	DMSO	77 mg/mL (198.7 mM)
	Water	Insoluble
	Ethanol	Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download 4-Hydroxytamoxifen (Afimoxifene) SDF

Molecular Weight	387.51
Formula	C₂₆H₂₉NO₂
CAS No.	68392-35-8
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	Afimoxifene
Smiles	CCC(=C(C1=CC=C(C=C1)O)C2=CC=C(C=C2)OCCN(C)C)C3=CC=CC=C3

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take μL DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2021-01-06)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT03199963	Terminated	Drug: 4-OH tamoxifen\|Drug: Placebo	Mammographic Breast Density	BHR Pharma LLC	August 21 2017	Phase 3

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Estrogen/progestogen Receptor Signaling Pathway Map

Related Estrogen/progestogen Receptor Products

Licochalcone A ^New

Licochalcone A is an estrogenic flavanoid extracted from licorice root, showing antimalarial, anticancer, antibacterial and antiviral activities. Phase 3.
Endoxifen HCl ^New

Endoxifen HCl, the active metabolite of Tamoxifen, ia a potent and selective estrogen receptor antagonist. Phase 2.
Sacubitril/valsartan (LCZ696) ^New

Sacubitril/valsartan (LCZ696, Sacubitril, Valsartan), consisting of valsartan and sacubitril in 1:1 molar ratio, is an orally bioavailable, dual-acting angiotensin receptor-neprilysin inhibitor (ARNi) for hypertension and heart failure. Phase 3.
Fulvestrant

Fulvestrant (ICI-182780, ZD 9238, ZM 182780) is an estrogen receptor (ER) antagonist with IC50 of 0.94 nM in a cell-free assay. Fulvestrant also induces autophagy and apoptosis and has antitumor activity.
Tamoxifen Citrate

Tamoxifen Citrate (ICI 46474) is a selective estrogen receptor modulator (SERM). Tamoxifen Citrate is also a potent Hsp90 activator and enhances the Hsp90 molecular chaperone ATPase activity. Tamoxifen induces apoptosis and autophagy.
Mifepristone

Mifepristone (RU486, C-1073, RU 38486, RU-486, Mifegyne) is a remarkably active antagonist of progesterone receptor and glucocorticoid receptor with IC50 of 0.2 nM and 2.6 nM, respectively. Mifepristone promotes cell autophagy and apoptosis, decreases Bcl-2 level and increases Beclin1 level, accompanied by weakened interaction between Bcl-2 and Beclin1.

Features:Mifepristone is the first approved medication for patients with endogenous cushing's syndrome.
Raloxifene HCl

Raloxifene (LY156758, Keoxifene) HCl a selective and orally active estrogen receptor modulator (SERM), which inhibits human cytosolic aldehyde oxidase-catalyzed phthalazine oxidation activity with IC50 of 5.7 nM.

Features:Raloxifene is as effective as tamoxifen in reducing the incidence of breast cancer in postmenopausal women at increased risk.
Estradiol

Estradiol (17β-estradiol, β-Estradiol, E2, 17β-Oestradiol) is a human sex hormone and steroid, and the primary female sex hormone. Estradiol upregulates IL-6 expression through the estrogen receptor β (ERβ) pathway.
Toremifene Citrate

Toremifene Citrate (NSC 613680) is an oral selective estrogen receptor modulator (SERM), used in the treatment of advanced breast cancer.
Progesterone

Progesterone (Pregn-4-ene-3,20-dione) is an endogenous steroid hormone involved in the menstrual cycle, pregnancy, and embryogenesis of humans and other species. A potent agonist of the nuclear progesterone receptor (nPR) with Kd of 1 nM; An agonist of the membrane progesterone receptors(mPRs); An antagonist of the σ1 receptor.

Choose Your Country or Region

By Signaling Pathways

By product type

4-Hydroxytamoxifen (Afimoxifene)